If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
New Product Development » New Product Planning
Download FREE Excerpt
20 Info Graphics
3 Data Graphics
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
Proposed by three Duke University professors in a 2006 Health Affairs academic paper, the FDA's priority review voucher was written into law in 2007. Under this law, developers of medicines for specified neglected or rare pediatric diseases receive a voucher for six-month priority review from the FDA to be redeemed with another product of choice or sold to another organization.
However, certain restrictions like the sunset clause have raised uncertainties around the value of priority review vouchers among biopharmaceutical companies. Moreover, for companies that are unsuccessful in their use of a priority review voucher, the cost of failure can be particularly high due to the cost to procure and use the voucher.
This study provides a brief overview of priority review vouchers, its benefits, recent developments and criticisms against the voucher program.
This study was created using multiple secondary research sources.